Antigen-Presenting Cell Production via Segmented Monocyte Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing immuno-stimulatory antigen-presenting cells, such as dendritic cells, often induce tolerance or immunosuppression, leading to adverse reactions and making it difficult to distinguish between effective immune responses and disease progression in cancer treatment.
Innovation Solution
A method involving the separation of antigen release from monocyte activation, where monocytes are activated in the absence of apoptotic agents to differentiate into immuno-stimulatory autologous antigen-presenting cells, which are then combined with disease-associated antigens to enhance anti-tumor immune responses without inducing tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monocytes are activated in the presence of apoptotic agents to produce antigen-presenting cells, then antigen presentation capability is improved, but tolerance or immunosuppression is induced leading to adverse reactions
Solution Approach 1:
The method separates the activation of monocytes from the exposure to apoptotic agents. Monocytes are activated in the absence of apoptotic agents to differentiate into dendritic cells, which are then combined with disease-associated antigens. This segmentation prevents the induction of tolerance while maintaining antigen presentation capability.
Solution Approach 2:
Monocytes are activated in advance in the absence of apoptotic agents to become immuno-stimulatory dendritic cells before being combined with antigens. This preliminary activation ensures the cells are primed for immune stimulation without being exposed to conditions that would induce tolerance.
2Productivity
If traditional methods are used to produce antigen-presenting cells, then cell production is achieved, but it is difficult to distinguish between effective immune responses and disease progression
Solution Approach 1:
The invention creates a visible distinction through the immuno-stimulatory phenotype of the produced cells. The activated dendritic cells exhibit specific characteristics (such as surface marker expression patterns) that clearly indicate an immune-stimulating state rather than a tolerogenic state, allowing clinicians to distinguish effective immune responses from disease progression.
3Quantity of substance
If apoptotic agents are used to release disease-associated antigens, then antigen availability is improved, but tolerance induction occurs reducing anti-tumor immunity
Solution Approach 1:
The method segments the antigen release process from the monocyte activation process. Disease-associated antigens are released from apoptotic disease-effector cells in a separate step, and then combined with pre-activated dendritic cells. This ensures antigen availability while preventing the tolerogenic effect that would occur if monocytes were activated in the presence of apoptotic agents.
Data Source
AI summary
The present invention relates to methods for producing immuno-stimulatory antigen-presenting cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.